Trial · NCT00824265
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Phase | STARTED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 183 | |
| Treatment Phase | STARTED | Fludarabine + Cyclophosphamide_ ITT Subjects | 182 | |
| Treatment Phase | COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 119 | |
| Treatment Phase | COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 102 | |
| Treatment Phase | NOT COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 64 | |
| Treatment Phase | NOT COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 80 | |
| Follow-up Phase | STARTED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 172 | |
| Follow-up Phase | STARTED | Fludarabine + Cyclophosphamide_ ITT Subjects | 160 | |
| Follow-up Phase | COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 154 | |
| Follow-up Phase | COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 129 | |
| Follow-up Phase | NOT COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 18 | |
| Follow-up Phase | NOT COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 31 | |
| Survival Follow-up Phase | STARTED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 96 | |
| Survival Follow-up Phase | STARTED | Fludarabine + Cyclophosphamide_ ITT Subjects | 89 | |
| Survival Follow-up Phase | COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 87 | |
| Survival Follow-up Phase | COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 73 | |
| Survival Follow-up Phase | NOT COMPLETED | Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects | 9 | |
| Survival Follow-up Phase | NOT COMPLETED | Fludarabine + Cyclophosphamide_ ITT Subjects | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00824265/flow